Skip to main content

Advertisement

Table 3 Stability study of optimized formulation EF 5

From: Flurbiprofen loaded ethosomes - transdermal delivery of anti-inflammatory effect in rat model

Time (days) Microscopic evaluation %Encapsulation efficiency
Ethosomal suspension (EF 5)
At 4 °C/60 ± 5RH (n = 3)
 Initial Smooth spherical vesicles 95 ± 1
 7 Smooth spherical vesicles 91.5 ± 2.3
 15 Smooth spherical vesicles 88.4 ± 3.2
 30 Smooth spherical vesicles 85.4 ± 1.2
 60 Rough spherical vesicles 80.7 ± 3.3
 90 Rough spherical vesicle 74.5 ± 1.4
At 25 °C/60 ± 5RH (n = 3)
 Initial Smooth spherical vesicles 95 ± 1
 7 Smooth spherical vesicles 89.5 ± 1.3
 15 Smooth spherical vesicles 86 ± 3
 30 Rough spherical vesicles 73.7 ± 1.8
 60 Agglomerate 68.2 ± 2
 90 Agglomerate 54.5 ± 1.4
Lyophilized ethosomal suspension (EF5)
At 4 °C/60 ± 5RH (n = 3)
 Initial Smooth spherical vesicles 95 ± 1
 7 Smooth spherical vesicles 93.5 ± 1.2
 15 Smooth spherical vesicles 89.5 ± 3.1
 30 Smooth spherical vesicles 86.43 ± 2
 60 Rough spherical vesicles 80.3 ± 1.2
 90 Rough spherical vesicles 78.3 ± 1.9
At 25 °C/60 ± 5RH (n = 3)
 Initial Smooth spherical vesicles 95 ± 1
 7 Smooth spherical vesicles 88.4 ± 1
 15 Rough spherical vesicles 81.7 ± 2.4
 30 Rough spherical vesicles 77.9 ± 3
 60 Rough spherical vesicles 71 ± 2.5
 90 Agglomerate 65.5 ± 2